HR Execs on the Move


 
Numira is a specialty preclinical CRO that combines innovative technologies and expertise to provide unique solutions to a wide variety of preclinical drug discovery efforts.   We support leading pharmaceutical, biotech, and medical device companies in the areas of discovery research and efficacy evaluation, offering services in the following areas - High-Resolution MicroCT Imaging, Image Analysis (microCT, MRI, ECG, histology data), Specialized Histology (GLP or non-GLP), 3D Oncology Cell Screening.   Utilizing our patented imaging reagents and powerful 3D visualization and analytic tools, we provide images, metrics, and analyses that will allow definitive answers much more rapidly and accurately than ...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.numirabio.com
  • 420 E. South Temple Suite 520
    Salt Lake City, UT USA 84111
  • Phone: 801.320.0682

Executives

Name Title Contact Details

Similar Companies

PacketDNA

PacketDNA Inc. is a Kanata, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ibis Biosciences a Division of Abbott

Ibis Biosciences a Division of Abbott is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GTx, Inc.

GTx, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

SelectX Pharmaceuticals

SelectX Pharmaceuticals, Inc. is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Pyxis Oncology

Founded by Longwood Fund, Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis is employing site-specific conjugation technology to develop highly stable ADCs with enhanced therapeutic indexes. Pyxis is also advancing a diverse portfolio of immunotherapies that target broad immune regulators as well as novel immune checkpoints identified through its immuno-oncology and cold tumor discovery efforts.